Perspective · 10 Sep 2026
Conference abstractPublished 20 Jul 2015
Differential regulation of NK cell functions by PI3K isoforms and mTOR complexes
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Phosphoinositide 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR) play fundamental roles in signal transduction for cell proliferation and survival. Recently, specific inhibitors of PI3K isoforms are being evaluated for their therapeutic potential in cancer. However, little is known about their roles in natural killer (NK) cell, an effector lymphocyte of innate immunity. Here we assessed how different classes of PI3K inhibitors and mTOR complex (mTORC) inhibitors affect the function of NK cells. Inhibitors of all class I isoforms (pan-PI3K) significantly impaired cell-mediated cytotoxicity and antibody-dependent cellular cytotoxicity of NK cells against tumor cells, whereas isoform-selective inhibitors had little effect; in particular, no significant effect was observed in NK cells treated with p110a-selective inhibitors. Production of cytokines and chemokines including IFN-g in NK cells stimulated through NKG2D and NK1.1 was blocked by a pan-PI3K inhibitor and partially reduced by a p110d inhibitor, with lesser effects of p110a inhibitors. NK cell-mediated cytotoxicity against tumor cells as well as IFN-g production through NKG2D were down-regulated by PP242, an inhibitor for both complex of mTOR, but not by rapamycin inhibiting mTORC1 only. In anti- NKG2D antibody-stimulated NK cells, pan-PI3K inhibitor decreased the phosphorylation of AKT and ERK1/2 phosphorylation, while p110a inhibition modestly reduced PI3K signaling output as measured by AKT and ERK1/2 phosphorylation. These results reveal the role of PI3K isoforms and mTOR complexes in NK cell functions and indicate that selective p110a inhibitors would provide a better therapeutic window for specific disease states than achieved by targeting all isoforms.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical and Cellular Immunology.
Commentary · 22 Jul 2026
From Bench to Bedside: Reframing the CXCL13/CXCR5 Axis as a Non-Redundant Organizer of Protective Pulmonary Immunity in COVID-19
Commentary · 17 Jul 2026
CD5L:p40, a third wheel to IL-12 and IL-23 biology?
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Cellular Immunology
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Sung Su Yea”
